Shanghai Biopharmaleader co.,ltd

Date: 18th July 2016
Cabozantinib CAS:849217-68-1
If you are going to consult the information about 849217-68-1 from one of the leading 849217-68-1 manufacturers and suppliers in China, Biopharmaleader Co.,Ltd is always at your service.Product InformationCAS NO.849217-68-1?Product NameCabozantinibSynonymsXL-184FormulaC28H24FN3O5Molecular Weight502Spec / Purity98%minSupply CapacityDetailsCabozantinib( XL-184) is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis.Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011.Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers.
Latest News
Contact Information



Building 11, NO. 3802 ShenGang Rd, Xinfei Corporation Home, SongJiang District, Shanghai,201611, China.
Shanghai, 201611


Contact Form